MandalMed, Inc.

To: Examiner Peter J. Reddig GAU 1642

Fax No. 571-273-~~2031~~ 8300

Date: January 22, 2007

From: Constance M. John

Pages: 7 including cover

Re: Appn. 10/726,198

Message: Enclosed please find the newly revised amendment and claims. Thank you for your kind assistance.

In the United States Patent and Trademark Office

Appn. Number:	10/726,198
Filing Date:	12/02/2003
Applicants:	John et al.
Appn. Title:	Sustained Release *N*-Terminally Truncated Galectin-3 and Antibodies to Galectin-3 Carbohydrate Ligands for Use in Treating Disease
Examiner:	Peter J. Reddig
GAU:	1642
Mailed:	

NEW VERSION OF AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA
22313-1450

Date: January 22, 2007

Sir:

In response to the Office Action for the above-identified patent application, mailing date 12/07/2006, kindly amend the above-identified application as follows:

Claims, Status:

Original claims 1-10, and 18-24 are pending in this application.

Claims 11-17 were withdrawn from consideration.

Claims 1-7, 8-10, and 18-24 are subject to restriction and/or election requirement.

Election and Amendment of Claims:

Election of Group I (Claims 1-7) and Seq. ID No: 1. Withdrawal of Claims 8-10, and 18-24. Claims 1-7 are submitted as follows.

Claim Election/Restrictions:

Claims 1-7 (Group I) are submitted for consideration. Claims 4 and 6 are currently amended. Claim 4 was amended to included use in treatment of specific diseases in

addition to cancer that was originally claimed. However, per the conversation I had with Examiner Peter J. Redding on Friday, January 19, 2007 I hereby elect only the treatment of cancer for consideration for Claim 4.

Please note: Claim 6 originally referred to SEQ ID NO: 2 but the reference was incorrect. SEQ ID NO: 2 is *N*-terminally truncated galectin-3 that is corresponding to SEQ ID NO: 1 but with a cysteine added to the *N*-terminus to enable thiol-specific derivatization. Claim 6 is currently amended to correctly refer to SEQ ID NO: 3 that is the sequence of the intact recombinant human galectin-3 protein containing both Tyr-63 and Asp-241. As described exactly in the Specification and Claims 1, 2 and (amended) Claim 6, *N*-terminally truncated galectin-3 can be produced that possesses activity as a treatment for disease. The desired *N*-terminally truncated recombinant human galectin-3 molecules that include SEQ ID NO: 1 are composed of a specific subset of the amino acid residues comprising SEQ ID NO: 3 that is described in the Specification and that is defined in Claim 6.

Very respectfully yours,

Constance John

Constance M. John, R.Ph., Ph.D.
MandalMed, Inc.
665 3rd Street, Suite 250
San Francisco, CA 94107

Tel.: 415-495-5570

Application/Control Number: 10/726,198
Attorney Docket No. 3157.00011
January 22, 2007

NEWLY AMENDED VERSION

CLAIMS

What is claimed is:

1. (original) A composition comprising an effective amount of *N*-terminally truncated galectin-3 and a pharmaceutically acceptable carrier.

2. (original) The composition according to claim 1, wherein said *N*-terminally truncated galectin-3 has a sequence according to SEQ ID No: 1 and analogues thereof.

3. (original) The composition according to claim 1, wherein said *N*-terminally truncated galectin-3 is present in an amount sufficient to reduce tumor size.

4. (currently amended) The composition according to claim 1 for use in treating rheumatoid arthritis, juvenile idiopathic arthritis, atherosclerotic cardiovascular disease, and cancer.

5. (original) The composition according to claim 1, wherein said *N*-terminally truncated galectin-3 has a sequence as set forth in SEQ ID No: 2 and analogues and homologues thereof.

6. (currently amended) The composition according to claim ~~5~~ 1, wherein said analogues and homologues include at least one set of polypeptides that include amino acid sequences of SEQ ID NO: ~~2~~3 beginning with an amino acid residue from Tyr-63 through Arg-129 and extendsing at least to an amino acide residue from Asp-241 through Ile-250.

7. (original) The composition according to claim 1, wherein said composition is formulated for slow release.

8. (withdrawn) A method of treating a tumor in a patient by administering to a patient in need of treatment an effective amount of N-terminally truncated galectin-3 according to claim 1, in a pharmaceutically acceptable carrier.

9. (withdrawn) The method according to claim 8, wherein said administering step includes administering N-terminally truncated galectin-3 having a sequence as set forth in SEQ ID No:2 and analogues and homologues thereof.

10. (withdrawn) The method according to claim 9, wherein said administering step includes administering analogues and homologues that include at least one set of polypeptides that include amino acid sequences of SEQ ID No:2 beginning with an amino acid residue from Try-63 through Arg-129 and extends at least to an amino acide residue from Asp-241 through Ile-250.

11. (withdrawn) A treatment treatment for cancer and inflammation comprising an effective amount of N-terminally truncated galectin-3 according to claim 1, and a pharmaceutically acceptable carrier.

12. (withdrawn) The treatment according to claim 11, wherein said N-terminally truncated galectin-3 wherein said N-terminally truncated galectin-3 has a sequence as set forth in SEQ ID No:2 and analogues and homologues thereof.

13. (withdrawn) The treatment according to claim 12, wherein said analogues and homologues include at least one set of polypeptides that include amino acid sequences of SEQ ID No:2 beginning with an amino acid residue from Try-63 through Arg-129 and extends at least to an amino acide residue from Asp-241 through Ile-250.

14. (withdrawn) The treatment according to claim 11, wherein said N-terminally truncated galectin-3 is present in an amount sufficient to prevent metastasis.

15. (withdrawn) An anti-cancer treatment comprising an effective amount of a nucleic acid sequence encoding an N-terminally truncated galectin-3 according to claim 1, and a pharmaceutically acceptable carrier.

16. (withdrawn) The treatment according to claim 13, wherein said nucleic acid sequence encoding the N-terminally truncated galectin-3 is present in an amount sufficient to prevent metastasis.

17. (withdrawn) The treatment according to claim 11, wherein said treatment is formulated for slow release.

18. (withdrawn) A nucleic acid sequence encoding for an N-terminally truncated galectin-3.

19. (withdrawn) The nucleic acid sequence according to claim 18, wherein said N-terminally truncated galectin-3 wherein said N-terminally truncated galectin-3 has a sequence as set forth in SEQ ID No:2 and analogues and homologues thereof.

20. (withdrawn) The nucleic acid sequences according to claim 19, wherein said analogues and homologues include at least one set of polypeptides that include amino acid sequences of SEQ ID No:2 beginning with an amino acid residue from Try-63 through Arg-129 and extends at least to an amino acide residue from Asp-241 through Ile-250.

21. (withdrawn) A method of treating a tumor in a patient by administering to a patient in need of treatment an effective amount of a nucleic acid sequence encoding an N-terminally truncated galectin-3 in a pharmaceutically acceptable carrier.

22. (withdrawn) The method according to claim 21, wherein said administering step includes administering the N-terminally truncated galectin-3 in a method selected from the group consisting essentially of intramuscularly, orally, intravenously, and locally.

23. (withdrawn) An antibody that specifically binds to carbohydrate ligands of galectin-3.

24. (withdrawn) The antibody according to claim 23, wherein said antibody is used for treating cancer.